Test Bank - Clayton’s Basic Pharmacology for Nurses, 19th edition (Willihnganz, 2023)

TestqhBankqhForqhClayton’sqhBasicqhPharmacologyqhforqhNursesqh19thqhEdi
tionqhByqhMichelleqhJ.qhWillihnganz,qhSamuelqhL.qhGurevitz,qhBruceqhCla
ytonqhComplete

,Chapterqh01:qhDrugqhDefinitions,qhStandards,qhandqhInformationqhSourcesqhWil
lihnganz:qhClayton’sqhBasicqhPharmacologyqhforqhNurses,qh19thqhEdition


MULTIPLEqhCHOIC
E

1. WhichqhnameqhidentifiesqhaqhdrugqhlistedqhbyqhtheqhUSqhF
oodqhandqhDrugqhAdministrationqh(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:qhC
Theqhofficialqhnameqhisqhtheqhnameqhunderqhwhichqhaqhdrugq
hisqhlistedqhbyqhtheqhFDA.qhTheqhbrandqhname,qhorqhtrademar
k,qhisqhtheqhnameqhgivenqhtoqhaqhdrugqhbyqhitsqhmanufacturer.
qhTheqhnonproprietary,qhorqhgeneric,qhnameqhisqhprovidedqhb
yqhtheqhUnitedqhStatesqhAdoptedqhNamesqhCouncil.
DIF: CognitiveqhLevel:qhKnowledge REF:qhp.qh9
OBJ:qh1NAT:qhNCLEXqhClientqhNeedsqhCategory:qhSafe,qhEffecti
veqhCareqhEnvironmentqhTOP:q h NursingqhProcessqhStep:qhAssessment
CON:q
hPatientqhEducation


2. Whichqhsourceqhcontainsqhinformationqhspecificqhtoqhnutritionalsupplements?
a. USPqhDictionaryqhofqhUSANqh&qhInternationalqhDrugqhNames
b. NaturalqhMedicinesqhComprehensiveqhDatabase
c. UnitedqhStatesqhPharmacopoeia/NationalqhFormularyqh(USPNF)
d. DrugqhInteractionqhFacts
ANS:qhC
UnitedqhStatesqhPharmacopoeia/NationalqhFormularyqhcontainsqhinformationqhspecificqhtoqhnu
tritionalqhsupplements.qhUSPqhDictionaryqhofqhUSANqh&qhInternationalqhDrugqhNamesqhisqhaq
hcompilationqhofqhdrugqhnames,qhpronunciationqhguide,qhandqhpossibleqhfutureqhFDAqhapprove
dqhdrugs;qhitqhdoesqhnotqhincludeqhnutritionalqhsupplements.qhNaturalqhMedicinesqhComprehen
siveqhDatabaseqhcontains
evidence-
basedqhinformationqhonqhherbalqhmedicinesqhandqhherbalqhcombinationqhproducts;qhitqhdoesqhno
tqhincludeqhinformationqhspecificqhtoqhnutritionalqhsupplements.qhDrugqhInteractionqhFactsqhco
ntainsqhcomprehensiveqhinformationqhonqhdrugqhinteractionqhfacts;qhitqhdoesqhnotqhincludeqhnut
ritionalqhsupplements.

DIF: CognitiveqhLevel:qhKnowledge REF:q h p.qh4
OBJ:qh3qhNAT:qhNCLEXqhClientqhNeedsqhCategory:qhPhysiologi
calqhIntegrity
TOP:q h NursingqhProcessqhStep:qhAssessment CON:qhNutritionqh|qhPatientqhEducation

3. Whichqhdrugqhreferenceqhcontainsqhdrugqhmonographsqhthatqhdescribeqhallqhdrugsqhinqhaqhtherapeuticqhcl
ass?
a. DrugqhFactsqhandqhComparisons

, b. DrugqhInteractionqhFacts
c. HandbookqhonqhInjectableqhDrugs
d. Martindale—TheqhCompleteqhDrugqhReference
ANS:qhA
DrugqhFactsqhandqhComparisonsqhcontainsqhdrugqhmonographsqhthatqhdescribeqhallqhd
rugsqhinqhaqhtherapeuticqhclass.qhMonographsqhareqhformattedqhasqhtablesqhtoqhallowqhc
omparisonqhofqhsimilarqhproducts,qhbrandqhnames,qhmanufacturers,qhcostqhindices,qhan
dqhavailableqhdosageqhformsqhOnlineqhversionqhisqhavailable.

DIF: CognitiveqhLevel:qhKnowledge REF:qhp.qh4qhTableqh1.2
OBJ:q h q h 3 NAT:qhNCLEXqhClientqhNeedsqhCategory:qhPhysiologicalqhIntegrity
TOP:q h NursingqhProcessqhStep:qhAssessment CON:qhSafetyqh|qhPatientqhEducationqh|qhClinicalqhJudgment

4. Whichqhdrugqhreferenceqhcontainsqhmonographsqhaboutqhvirtuallyqheveryqhsingle-
entitydrugqhavailableqhinqhtheqhUnitedqhStatesqhandqhdescribesqhtherapeuticqhusesqhofqhdrugs,
qhincludingqhapprovedqhandqhunapprovedqhuses?
a. Martindale:qhTheqhCompleteqhDrugqhReference
b. AHFSqhDrugqhInformation
c. DrugqhReference
d. DrugqhFactsqhandqhComparisons
ANS:qhB
AHFSqhDrugqhInformationqhcontainsqhmonographsqhaboutqhvirtuallyqheveryqhsingle-
entityqhdrugqhavailableqhinqhtheqhUnitedqhStatesqhandqhdescribesqhtherapeuticqhusesqhofqhdrugs,q
hincludingqhapprovedqhandqhunapprovedqhuses.


DIF: CognitiveqhLevel:qhKnowledge REF:qhp.qh4qhTableqh1.2
OBJ:q h q h 3 NAT:qhNCLEXqhClientqhNeedsqhCategory:qhPhysiologicalqhIntegrity
TOP:q h NursingqhProcessqhStep:qhPlanning CON:qhSafetyqh|qhPatientqhEducationqh|qhClinicalqhJudgment

5. Whichqhonlineqhdrugqhreferenceqhmakesqhavailableqhtoqhhealthcareqhprovidersqhandqhtheqh
publicqhaqhstandard,qhcomprehensive,qhup-to-
dateqhlookqhupqhandqhdownloadableqhresourceqhaboutqhmedicines?
a. AmericanqhDrugqhIndex
b. AmericanqhHospitalqhFormulary
c. DailyMed
d. DrugqhReference
ANS:qhC
DailyMedqhmakesqhavailableqhtoqhhealthcareqhprovidersqhandqhtheqhpublicqhaqhstandard,qhcom
prehensive,qhup-to-
dateqhlookqhupqhandqhdownloadableqhresourceqhaboutqhmedicines.qhTheqhAmericanqhDrugqhIn
dexqhisqhnotqhappropriateqhforqhpatientqhuse.qhTheqhAmericanqhHospitalqhFormularyqhisqhnotqh
appropriateqhforqhpatientqhuse.qhTheqhdrugqhreferenceqhisqhnotqhappropriateqhforqhpatientqhuse.

DIF: CognitiveqhLevel:qhKnowledge REF:q h p.qh3qh|p.qh4
OBJ:qh3qhNAT:qhNCLEXqhClientqhNeedsqhCategory:qhPhysiologi
calqhIntegrity
TOP:qhNursingqhProcessqhStep:qhImplementation
CON:qhSafetyqh|qhPatientqhEducationqh|qhClinicalqhJudgment

6. WhichqhlegislationqhauthorizesqhtheqhFDAqhtoqhdetermineqhtheqhsafetyqhofqhaqhdrugqhbeforeqhitsqhmarketin
g?
a. FederalqhFood,qhDrug,qhandqhCosmeticqhActqh(1938)
b. DurhamqhHumphreyqhAmendmentqh(1952)

, c. ControlledqhSubstancesqhActqh(1970)
d. KefauverqhHarrisqhDrugqhAmendmentqh(1962)

ANS:qhA
TheqhFederalqhFood,qhDrug,qhandqhCosmeticqhActqhofqh1938qhauthorizedqhtheqhFDAqhtoqhdeter
mineqhtheqhsafetyqhofqhallqhdrugsqhbeforeqhmarketing.qhLaterqhamendmentsqhandqhactsqhhelpedq
htightenqhFDAqhcontrolqhandqhensureqhdrugqhsafety.qhTheqhDurhamqhHumphreyqhAmendmentq
hdefinesqhtheqhkindsqhofqhdrugsqhthatqhcannotqhbeqhusedqhsafelyqhwithoutqhmedicalqhsupervisio
nqhandqhrestrictsqhtheirqhsaleqhtoqhprescriptionqhbyqhaqhlicensedqhpractitioner.qhTheqhControlledq
hSubstancesqhActqhaddressesqhonlyqhcontrolledqhsubstancesqhandqhtheirqhcategorization.qhTheqh
KefauverqhHarrisqhDrugqhAmendmentqhensuresqhdrugqhefficacyqhandqhgreaterqhdrugqhsafety.qh
DrugqhmanufacturersqhareqhrequiredqhtoqhproveqhtoqhtheqhFDAqhtheqheffectivenessqhofqhtheirqhp
roductsqhbeforeqhmarketingqhthem.

DIF: CognitiveqhLevel:qhKnowledge REF:qhp.qh5qhTableqhl.3
OBJ:q h 5
NAT:qhNCLEXqhClientqhNeedsqhCategory:qhPhysiologicalqhIn
tegrityqhTOP:qhNursingqhProcessqhStep:qhAssessment
CON:qhSafetyqh|qhPatientqhEducationqh|qhEvidenceqh|qhHealthqhCareqhLaw

7. Whichqhclassificationqhdoesqhmeperidineqh(Demerol)qhfallqhunder?
a. I
b. II
c. III
d. IV
ANS:qhB
Meperidineqh(Demerol)qhisqhaqhScheduleqhIIqhdrug;qhitqhhasqhaqhhighqhpotentialqhforqhabuseqhan
dqhmayqhleadqhtoqhsevereqhpsychologicalqhandqhphysicalqhdependence.qhScheduleqhIqhdrugsqhha
veqhhighqhpotentialqhforqhabuseqhandqhnoqhrecognizedqhmedicalqhuse.qhScheduleqhIIIqhdrugsqhha
veqhsomeqhpotentialqhforqhabuse.qhUseqhmayqhleadqhtoqhlowqhtoqhmoderateqhphysicalqhdepende
nceqhorqhhighqhpsychologicalqhdependence.qhScheduleqhIVqhdrugsqhhaveqhlowqhpotentialqhforqh
abuse.qhUseqhmayqhleadqhtoqhlimitedqhphysicalqhorqhpsychologicalqhdependence.

DIF: CognitiveqhLevel:qhKnowledge REF:q h p.qh10
OBJ:qh2qhNAT:qhNCLEXqhClientqhNeedsqhCategory:qhSafe,qhEffe
ctiveqhCareqhEnvironment
TOP:q h NursingqhProcessqhStep:qhAssessment CON:qhPatientqhEducationqh|qhAddictionqh|qhPain

8. WhichqhactionqhwouldqhtheqhFDAqhtakeqhtoqhexpediteqhdrugqhdevelopmentqhandqhapprovalqhforqh
anqhoutbreakqhofqhsmallpox?
a. Listqhsmallpoxqhasqhaqhhealthqhorphandisease.
b. Omitqhtheqhpreclinicalqhresearchphase.
c. Extendqhtheqhclinicalqhresearchqhphase.
d. Fastqhtrackqhtheqhinvestigationalqhdrug.
ANS:qhD
OnceqhtheqhInvestigationalqhNewqhDrugqhApplicationqhhasqhbeenqhapproved,qhtheqhdrugqhcanq
hreceiveqhhighestqhpriorityqhwithinqhtheqhagency,qhwhichqhisqhcalledqhfastqhtracking.qhAqhsmall
poxqhoutbreakqhwouldqhbecomeqhaqhpriorityqhconcernqhinqhtheqhworld.qhOrphanqhdiseasesqhare
qhnotqhresearchedqhinqhaqhpriorityqhmanner.qhPreclinicalqhresearchqhisqhnotqhomitted.qhExtendin
gqhanyqhphaseqhofqhtheqhresearchqhwouldqhmeanqhaqhlongerqhtimeqhtoqhdevelopqhaqhvaccine.qhTh
eqhFDAqhmustqhensureqhthatqhallqhphasesqhofqhtheqhpreclinicalqhandqhclinicalqhresearchqhphaseqh
haveqhbeenqhcompletedqhinqhaqhsafeqhmanner.

DIF: CognitiveqhLevel:qhKnowledge REF:q h q h p.qh7 OBJ:qh 5